主要文件

查看所有文档

M2699

马立马司他

Name: 马立马司他
Brand: SIGMA

≥98% (HPLC), solid, MMP inhibitor

别名:

BB2516, (2S,3R)-N4- [(1S)-2,2-二甲基-1- [（甲氨基）羰基] 丙基]-N1,2-二羟基-3-（2-甲基丙基）丁二酰胺

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₅H₂₉N₃O₅

化学文摘社编号:

154039-60-8

分子量:

331.41

UNSPSC Code:

12352200

PubChem Substance ID:

329817950

NACRES:

NA.77

MDL number:

MFCD00866242

Assay:

≥98% (HPLC)

Form:

solid

Quality level:

100

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

产品名称

马立马司他, ≥98% (HPLC)

Quality Level

100

assay

≥98% (HPLC)

form

solid

solubility

DMSO: ≥20 mg/mL

shipped in

wet ice

storage temp.

−20°C

SMILES string

CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)C

InChI

1S/C15H29N3O5/c1-8(2)7-9(10(19)13(21)18-23)12(20)17-11(14(22)16-6)15(3,4)5/h8-11,19,23H,7H2,1-6H3,(H,16,22)(H,17,20)(H,18,21)/t9-,10+,11-/m1/s1

InChI key

OCSMOTCMPXTDND-OUAUKWLOSA-N

Gene Information

—

说明

Application

Marimastat已用作下列抑制剂：

金属蛋白酶2/9 (MMP2/9)，以研究其对小鼠运动介导的白细胞介素-6 (IL-6)释放的影响
金属蛋白酶，测定铜绿假单胞菌培养物中的蛋白酶活性
金属蛋白酶10 (MMP10)，研究其对结合MMP10的单克隆抗体H3的影响

Biochem/physiol Actions

Marimastat 是一种广谱基质金属蛋白酶 (MMP) 抑制剂

Still not finding the right product?

Explore all of our products under 马立马司他

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases.

Aura D Urribarri et al.

Gut, 63(10), 1658-1667 (2014-01-18)

Polycystic liver diseases (PCLDs) are genetic disorders characterised by progressive bile duct dilatation and/or cyst development. Their pathogenesis is a consequence of hyperproliferation, hypersecretion and microRNA alterations in cholangiocytes. Here we evaluate the role of matrix metalloproteases (MMPs) in the

Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice.

Vincent E de Meijer et al.

PloS one, 5(6), e11256-e11256 (2010-07-02)

Liver fibrosis is characterized by excessive synthesis of extracellular matrix proteins, which prevails over their enzymatic degradation, primarily by matrix metalloproteinases (MMPs). The effect of pharmacological MMP inhibition on fibrogenesis, however, is largely unexplored. Inflammation is considered a prerequisite and

Studies of a cobalt(III) complex of the MMP inhibitor marimastat: a potential hypoxia-activated prodrug.

Timothy W Failes et al.

Chemistry (Weinheim an der Bergstrasse, Germany), 13(10), 2974-2982 (2006-12-16)

We report a potential means of selectively delivering matrix metalloproteinase (MMP) inhibitors to target tumour sites by use of a bioreductively activated Co(III) carrier system. The carrier, comprising a Co(III) complex of the tripodal ligand tris(methylpyridyl)amine (tpa), was investigated with

查看所有相关文献

全球贸易项目编号

货号	GTIN
M2699-25MG	04061833212981
M2699-5MG	04061833212998